- CBD-based products have become increasingly popular among professional athletes, primarily due to pain-relieving, anti-inflammatory qualities
- CannAssist International’s Xceptor Labs is an active player within the CBD-based product sector through the development of its proprietary CiBiDinol technology
- CiBiDinol’s technology, using a water-soluble carrier, developed an encapsulation process to deliver unchanged CBD molecule through cell’s watery matrix
- Xceptor Labs has seen rapid uptake in products’ popularity, with ten products now available for sale online
When three-time National Football League tight end Rob Gronkowski first announced his retirement from professional football, he attributed part of the decision to the heavy toll that injuries and nine subsequent surgeries had had on his ravaged body. However, the use of cannabidiol (“CBD”)-based topical pain relief products and the significant benefit provided by these played a large part in influencing the Super Bowl-winning athlete to return to the professional sports arena. CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to capitalize on the growing prominence CBD-based products within professional sports through its innovative technology and proprietary product portfolio.
The chronic use of over-the-counter pain relievers (i.e., nonsteroidal anti-inflammatory drugs or NSAIDs) and opioids are widely documented as posing more significant health risks previously known, with opioid addictions leading to the deaths of thousands of Americans annually. In such a landscape, professional athletes have been eager to learn about the pain relief and inflammation-reducing qualities found in CBD products while forgoing the risks commonly associated with NSAIDs or opioids. The interest in CBD for pain alleviation has only gained further momentum following the World Anti-Doping Agency (“WADA”) and the US Anti-Doping Agency (“USADA”) ‘s joint decision to remove CBD from their list of prohibited substances – in or out of competition (https://ibn.fm/8aXyt).
In a sector that has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly-owned Xceptor Labs has sought to differentiate itself through the use and development CiBiDinol technology. CiBiDinol’s technological make-up is a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules. These advantages in delivery, bioavailability and short shelf-life (https://ibn.fm/uigze) have been verified with third-party testing habitually demonstrating a 300% increase in gut absorption rate and a 400% increase in skin penetration for CiBiDinol relative to regular oil-based CBD (https://ibn.fm/n0x1m).
Perhaps more critically, the product’s effective absorption has also allowed for lower dosage requirements, thereby significantly lowering the amount of CBD needed to achieve its targeted endpoints.
In September 2020, Xceptol brand pain creams containing CiBiDinol were released; each cream carries FDA-registered ingredients, designed to provide localized fast-acting relief for sore, aching muscles and joints. In December 2020, the company added seven more SKU’s that include capsules and drops; Xceptol’s full range of consumer products is now available on www.xceptol.com and www.RangeMe.com, a site dedicated to vetting brands for large retailers.
“This is exciting news for us on many fronts; a process estimated to take weeks we accomplished in a few days – a testament, I feel, to the quality of the Xceptol brand,” noted CannAssist CEO Mark Palumbo regarding the news. “Also gratifying is being included on the RangeMe website, a significant portal for major retailers to find products for their customers.”
The global CBD industry is set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/SI4g6), CannAssist International seems advantageously positioned to benefit from the ongoing upswell in interest in CBD.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC